389 related articles for article (PubMed ID: 26255991)
41. Assessment of insulin resistance in lean women with polycystic ovary syndrome.
Morciano A; Romani F; Sagnella F; Scarinci E; Palla C; Moro F; Tropea A; Policola C; Della Casa S; Guido M; Lanzone A; Apa R
Fertil Steril; 2014 Jul; 102(1):250-256.e3. PubMed ID: 24825420
[TBL] [Abstract][Full Text] [Related]
42. Polycystic ovary syndrome influences the level of serum amyloid A and activity of phospholipid transfer protein in HDL₂ and HDL₃.
Gidwani S; Phelan N; McGill J; McGowan A; O'Connor A; Young IS; Gibney J; McEneny J
Hum Reprod; 2014 Jul; 29(7):1518-25. PubMed ID: 24842896
[TBL] [Abstract][Full Text] [Related]
43. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity.
Mather KJ; Kwan F; Corenblum B
Fertil Steril; 2000 Jan; 73(1):150-6. PubMed ID: 10632431
[TBL] [Abstract][Full Text] [Related]
44. Normal metabolic flexibility despite insulin resistance women with polycystic ovary syndrome.
Adamska A; Karczewska-Kupczewska M; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
Endocr J; 2013; 60(9):1107-13. PubMed ID: 23801024
[TBL] [Abstract][Full Text] [Related]
45. Detailed characterisation of circulatory nitric oxide and free radical indices--is there evidence for abnormal cardiovascular homeostasis in young women with polycystic ovary syndrome?
Willis GR; Udiawar M; Evans WD; Blundell HL; James PE; Rees DA
BJOG; 2014 Dec; 121(13):1596-603. PubMed ID: 24816317
[TBL] [Abstract][Full Text] [Related]
46. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome.
Zueff LF; Martins WP; Vieira CS; Ferriani RA
Ultrasound Obstet Gynecol; 2012 Mar; 39(3):341-7. PubMed ID: 21898634
[TBL] [Abstract][Full Text] [Related]
47. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome.
Adali E; Yildizhan R; Kurdoglu M; Bugdayci G; Kolusari A; Sahin HG
Fertil Steril; 2010 Jul; 94(2):666-72. PubMed ID: 19368913
[TBL] [Abstract][Full Text] [Related]
48. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.
Valkenburg O; Steegers-Theunissen RP; Smedts HP; Dallinga-Thie GM; Fauser BC; Westerveld EH; Laven JS
J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772
[TBL] [Abstract][Full Text] [Related]
49. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
[TBL] [Abstract][Full Text] [Related]
50. Endogenous thrombin potential in polycystic ovary syndrome: the association to body mass index, insulin resistance, and inflammation.
Aziz M; Sidelmann JJ; Wissing ML; Faber J; Skouby SO
Gynecol Endocrinol; 2015; 31(9):720-4. PubMed ID: 26291802
[TBL] [Abstract][Full Text] [Related]
51. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome.
Tosi F; Dorizzi R; Castello R; Maffeis C; Spiazzi G; Zoppini G; Muggeo M; Moghetti P
Eur J Endocrinol; 2009 Nov; 161(5):737-45. PubMed ID: 19713424
[TBL] [Abstract][Full Text] [Related]
52. Using metabolic markers to identify insulin resistance in premenopausal women with and without polycystic ovary syndrome.
Blum MR; Popat RA; Nagy A; Cataldo NA; McLaughlin TL
J Endocrinol Invest; 2021 Oct; 44(10):2123-2130. PubMed ID: 33687700
[TBL] [Abstract][Full Text] [Related]
53. Polycystic ovary syndrome is a risk factor for sarcopenic obesity: a case control study.
McBreairty LE; Chilibeck PD; Gordon JJ; Chizen DR; Zello GA
BMC Endocr Disord; 2019 Jul; 19(1):70. PubMed ID: 31262307
[TBL] [Abstract][Full Text] [Related]
54. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Wolczynski S; Gorska M
Hum Reprod; 2007 Jul; 22(7):1824-9. PubMed ID: 17582143
[TBL] [Abstract][Full Text] [Related]
55. Vitamin D and metabolic disturbances in polycystic ovary syndrome (PCOS): A cross-sectional study.
Krul-Poel YHM; Koenders PP; Steegers-Theunissen RP; Ten Boekel E; Wee MMT; Louwers Y; Lips P; Laven JSE; Simsek S
PLoS One; 2018; 13(12):e0204748. PubMed ID: 30513089
[TBL] [Abstract][Full Text] [Related]
56. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome.
Verit FF
Arch Gynecol Obstet; 2010 Jun; 281(6):1009-14. PubMed ID: 19771438
[TBL] [Abstract][Full Text] [Related]
57. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome.
Svendsen PF; Nilas L; Nørgaard K; Jensen JE; Madsbad S
Hum Reprod; 2008 Sep; 23(9):2113-21. PubMed ID: 18556679
[TBL] [Abstract][Full Text] [Related]
58. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance.
O'Connor A; Phelan N; Tun TK; Boran G; Gibney J; Roche HM
J Clin Endocrinol Metab; 2010 Mar; 95(3):1378-85. PubMed ID: 20080859
[TBL] [Abstract][Full Text] [Related]
59. A visceral adiposity index-related dietary pattern and the cardiometabolic profiles in women with polycystic ovary syndrome.
Ehsani B; Moslehi N; Mirmiran P; Ramezani Tehrani F; Tahmasebinejad Z; Azizi F
Clin Nutr; 2016 Oct; 35(5):1181-7. PubMed ID: 26699405
[TBL] [Abstract][Full Text] [Related]
60. Anti-Mullerian hormone and insulin resistance in polycystic ovary syndrome.
Fonseca HP; Brondi RS; Piovesan FX; Miklos TG; Aldrighi JM
Gynecol Endocrinol; 2014 Sep; 30(9):667-70. PubMed ID: 24898132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
